HGF
HGF (Hepatocyte growth factor) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 5 more.
Overview
Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerisation. Activates MAPK signalling following TMPRSS13 cleavage and activation.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming MET Tyrosine Kinase Inhibitor SGX523. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes clinical 0.65, affected pathway 0.73, literature 1.00, genetic association 0.50, somatic mutation 0.83). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Small Cell Lung Cancer. In OnCo, 1 product record names it (Ficlatuzumab).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · HGF (Hepatocyte growth factor) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 5 more.
- 1 · What it is
HGF (Hepatocyte growth factor) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 5 more.
- 2 · What goes wrong in cancer
Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types.
- 3 · How drugs use it
No product in this corpus aims at HGF yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:4893 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P14210 (protein name, function text, keywords and locations (REST API)); CIViC gene HGF (1 evidence items, 0 assertions, 1 variants; diseases: Glioblastoma (GraphQL API, CC0)); Open Targets ENSG00000019991 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.54, gastric cancer 0.59, ovarian cancer 0.51, melanoma 0.55, skin cancer 0.55, lung cancer 0.62 (GraphQL API, CC0)); IntOGen HGF (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerisation. Activates MAPK signalling following TMPRSS13 cleavage and activation. Locus 7q21.11 (HGNC).
- Lung cancer: Open Targets association 0.62 with lung cancer (MONDO_0008903)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.59 with gastric cancer (MONDO_0001056)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Ovarian cancer: Open Targets association 0.51 with ovarian cancer (MONDO_0008170)
- Glioma & glioblastoma: CIViC evidence names this disease
- Small-cell lung cancer: IntOGen driver in 1 cohort (SCLC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.65; IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"HGF" OR ABSTRACT:"HGF" OR TITLE:"hepatocyte growth factor" OR ABSTRACT:"hepatocyte growth factor" OR TITLE:"Hepatocyte growth factor" OR ABSTRACT:"Hepatocyte growth factor" OR TITLE:"F-TCF" OR ABSTRACT:"F-TCF" OR TITLE:"DFNB39" OR ABSTRACT:"DFNB39") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HGF, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetRICTOR
Shares Lung cancer (all types), Skin cancer (all types), CIViC, Gastric & gastro-oesophageal junction cancer.
- TargetBARD1
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetDROSHA
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCRLF2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetNUTM1
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Ovarian cancer.
- TargetRASA1
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetLZTR1
Shares Lung cancer (all types), Skin cancer (all types), Glioma & glioblastoma, CIViC.